Skip to content
DataLookout
Menu

RELIEFNCT07408219

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

StatusRecruiting
PhaseNot specified
Primary completion (estimated)

At risk: Primary completion moved at least 3 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Primary and study completion pushed from Sep 30, 2026 to Dec 31, 2026
  2. Notable Primary and study completion pushed from Mar 31, 2026 to Sep 30, 2026v3
  3. Minor Start date: Jan 14, 2026 to Jan 17, 2026v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change From Baseline in Urticaria Control Test - 7 Day Recall (UCT-7) Score at Week 4 in Patients Initiating Remibrutinib
Timeframe: Baseline and Week 4

Secondary (6)

Change From Baseline in UCT-7 Score at Week 1 in Patients Initiating Remibrutinib
Proportion of Patients With a UCT-7 Score ≥12 at Week 1 and Week 4 in Patients Initiating Remibrutinib
Treatment Satisfaction Questionnaire for Medication - Version 9 (TSQM-9) Domain Scores at Week 4 in Patients Initiating Remibrutinib
Change From Baseline in TSQM-9 Domain Scores at Week 4 in Patients Initiating Remibrutinib
Treatment Satisfaction Assessed by TSQM-9 Overall Score at Week 4 in Patients Initiating Remibrutinib
Show 1 moreShow less
Change From Baseline in TSQM-9 Overall Score at Week 4 in Patients Initiating Remibrutinib

Arms and interventions

Remibrutinib Cohort

Adult patients with CSU who are prescribed and initiating treatment with remibrutinib.

Dupilumab Cohort

Adult patients with CSU who are prescribed and initiating treatment with dupilumab.

Sites

1 site in 1 country

  • NovartisEast Hanover, New Jersey, United States